PRDM16
PRDM16 (Histone-lysine N-methyltransferase PRDM16) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Breast cancer, Neuroendocrine tumours and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcription regulator that acts both as a histone methyltransferase or chromatin adapter, depending on the context. In the cytoplasm, acts as a histone methyltransferase, which catalyses monomethylation of 'Lys-9' of free histone H3 (H3K9me1) during translation. Monomethylated histone H3 is then transported to the nucleus and incorporated into nucleosomes where SUV39H methyltransferases (SUV39H1 and SUV39H2) use it as a substrate to catalyse histone H3 'Lys-9' trimethylation (H3K9me3). Probably one of the primary histone methyltransferases along with MECOM/PRDM3 that direct cytoplasmic H3K9me1 methylation. In the nucleus, acts as a key chromatin adapter that mediates differentiation of brown and beige adipocytes, which are specialised in dissipating chemical energy in the form of heat in response to cold or excess feeding. Following recruitment to chromatin by PPARG nuclear receptor, promotes differentiation of myoblastic precursors into brown adipose cells. Location: Nucleus; Chromosome; Cytoplasm (UniProt). Locus 1p36.32 (HGNC).
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Breast cancer: Open Targets association 0.56 with breast cancer (MONDO_0007254)
- Neuroendocrine tumours: Open Targets association 0.55 with neuroendocrine neoplasm (MONDO_0019496)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Sarcomas: Open Targets association 0.51 with sarcoma (MONDO_0005089)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"PRDM16" OR ABSTRACT:"PRDM16" OR TITLE:"PR/SET domain 16" OR ABSTRACT:"PR/SET domain 16" OR TITLE:"Histone-lysine N-methyltransferase PRDM16" OR ABSTRACT:"Histone-lysine N-methyltransferase PRDM16" OR TITLE:"MEL1" OR ABSTRACT:"MEL1" OR TITLE:"PFM13" OR ABSTRACT:"PFM13" OR TITLE:"KIAA1675" OR ABSTRACT:"KIAA1675") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRDM16, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/prdm16.json. Licence CC BY-NC 4.0.